ONCAlert | 2018 ASCO Annual Meeting

Pembrolizumab for TNBC

Sara Hurvitz, MD
Published Online: 10:19 PM, Wed December 10, 2014
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses the results of a study looking at pembrolizumab (Keytruda) in patients with triple-negative breast cancer (TNBC).

Clinical Pearls

  • Inhibiting the PD-1 pathway showed activity in advanced TNBC in a previous phase I study.
  • In this study, a heavily pretreated population of patients with TNBC tolerated pembrolizumab well. Durable responses were observed.
  • There remains a need for breast cancer doctors to understand how to manage toxicities associated with immunotherapies.

<<< Go back to the SABCS conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.